RheumNow Week in Review – 22 July 2016

Save

From tofacitinib developmental trials in RA and psoriasis and adherence to T2T in early RA to a rheumatology pearl about dapsone and much more, here are the highlights of what you may have missed on RheumNow.com this week.

FDA Panel Recommends Brodalumab Approval in Psoriasis

Save

Valeant Pharmaceuticals International's experimental drug to treat psoriasis should be approved as long as certain measures are put in place to mitigate the risk of suicide, an advisory committee to the U.S. Food and Drug Administration concluded on Tuesday.

Sandoz Etanercept Biosimilar Voted for Approval by FDA Arthritis Advisory Committee

Save

The Food and Drug Administration’s Arthritis Advisory Committee (AAC) yesterday recommended that the Sandoz etanercept (Enbrel) biosimilar (GP-2015) be approved for use in the United States.

New EULAR Guidelines on Behçet's

Save

At the EULAR 2016 meeting, new EULAR recommendations for the management of Behçet's disease (BD) were presented.

Ixekizumab Success with the UNCOVER Trials in Psoriasis

Save

The NEJM today published the results of two phase-3 trials (UNCOVER-2 and UNCOVER-3) demonstrating the efficacy of ixekizumab (a monoclonal antibody against interleukin-17A) in the treatment of moderate-to-severe psoriasis.

Mosquito Arthritis

Save

In the last two years there have been increasing reports of mosquito-borne infectious arthritides.  Dengue fever was best known until the introduction of viral infections due to chikungunya and Zika. 

TB Management Questions

Save

The following is a compilation of several frequently asked questions regarding tuberculosis (TB) testing or treatment in patients on a TNF inhibitor (TNFi) or other biologic agents.

Secukinumab Improves Patient-Reported Outcomes in Psoriatic Arthritis (FUTURE 1)

Save

Secukinumab (Cosentyx) has recently been approved for use in ankylosing spondylitis and psoriatic arthritis; the latter largely based on the FUTURE 2 and the just reported FUTURE 1 clinical trial. FUTURE 1 demonstrates the efficacy and safety of secukinumab, with inital weekly intravenous loading, given monthly as a subcutaneous injection. 

The RheumNow Week in Review – 6 May 2016

Save

Watch Dr. Cush discuss the highlights from this week on RheumNow.com.

Poor Outcomes for Dermato/Polymyositis Admitted to ICU

Save

Idiopathic inflammatory myopathies (IIMs) may be complicated with life-threatening conditions requiring intensive care unit (ICU) admission.  The outcomes of such complications may be dire, but there are few series addressing the outcomes of those admitted to the ICU. 

HLA-B*5801 Testing Needed in Asians and Blacks with Gout

Save

Choi and colleagues analyzed US hospitalizations (2009–2013) to assess the frequency and racial distribution of patients hospitalized with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) related to the use of urate-lowering (ULT) therapy (predominantly allopurinol).

Does Psoriasis Increase Risk of Abdominal Aneurysm?

Save

Danish researchers studied a cohort of 59,423 mild psoriasis and 11,566 severe psoriasis patients over a 14 year period, and found 240 and 50 cases of abdominal aortic aneurysms (AAA), repectively. (Citation source http://buff.ly/1YxGpDA)

RheumNow Week in Review - 8 April 2016

Save

Dr. Jack Cush reviews the rheumatology highlights from the news, media, and journals from this past week:

Tofacitinib Efficacy Revealed in OPAL Study

Save

Pfizer has issued a press release of its preliminary results from the OPAL study that examined the efficacy and safety of tofacitinib 5 mg and 10 mg twice daily (BID) in adults active psoriatic arthritis (PsA).

Severe Psoriasis Associated with a Renal Disease Risk

Save

There have been several reports of psoriasis being linked to chronic renal disease in the literature. Another population-based study has also found a link between severe psoriasis and kidney disease. 

Incidence of Psoriatic Arthritis Among Psoriasis Patients

Save

Researchers at the University of Toronto have prospectively studied a cohort of 464 psoriasis patients without a diagnosis of arthritis and followed them over 8 years to estimate the incidence and frequency of psoriatic arthritis (PsA). 

Week in Review - 25 March 2016

Save

1. phase 3, BRIDGE study shows romosozumab (anti-sclerostin MAb) significantly increases lumbar BMD in men with osteoporosis


2. Statin use is associated with a 21% increased risk of skin cancer (NMSC) - data

FDA Approves Taltz for Psoriasis

Save

Tuesday the FDA approved the IL-17 inhibitor, Taltz (ixekizumab) for adults with moderate to severe plaque psoriasis. (Citation source http://buff.ly/1py10wd) 

Ixekizumab Superior to Etanercept in Psoriasis

Save

The UNCOVER-2 and UNCOVER-3 trials were presented at the American Academy of Dermatology (AAD) Annual Meeting taking this week in Washington, D.C.

Subclinical Synovitis in Psoriasis Portends Future Psoriatic Arthritis

Save

It is estimated that nearly 30% of psoriasis patients will develop psoriatic arthritis (PsA).  This prevalence was studied by performing MRI scans on asymptomatic psoriasis (n=56) and 30 control patients without arthritis.